Hyperprogression after Acquisition of Resistance Mutation to Alectinib in a Patient with Lung Adenocarcinoma: Case Report
DOI:
https://doi.org/10.32635/2176-9745.RBC.2025v71n3.5098Keywords:
Adenocarcinoma of Lung , Oncogene Fusion, Oncogene Proteins , High-Throughput Nucleotide SequencingAbstract
Introduction: The mutation in the gene anaplastic lymphoma kinase (ALK) occurs in approximately 3% to 5% of patients with lung adenocarcinoma, being more frequent in younger patients, non-smokers, or light smokers. Due to its molecular specificity, treatment involves the use of targeted therapies with ALK inhibitors, such as alectinib and lorlatinib, which have shown significant efficacy in blocking the abnormal activity of the protein. Case report: Young male patient diagnosed with metastatic lung adenocarcinoma to the pleura, associated with a genetic rearrangement of the ALK gene, featuring a new early mutation. The study describes the treatment with targeted therapies and clinical complications throughout the course of the disease. Due to complications and limitations for invasive interventions, the patient died one year and two months after his diagnosis. Conclusion: The study reinforces the importance of early diagnosis with specific tests and highlights the challenges of treatment, discussing new therapies and their obstacles to improve survival rates in advanced tumors.
Downloads
References
Instituto Nacional de Câncer [Internet]. Rio de Janeiro: INCA; 2022. Câncer de pulmão, 2022 [acesso 2024 jul 18]. Disponível em: http://www.gov.br/inca/pt-br/assuntos/cancer/tipos/pulmao
Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244-85. doi: https://doi.org/10.1097/JTO.0b013e318206a221 DOI: https://doi.org/10.1097/JTO.0b013e318206a221
Rani B, Khan A, Hussain M, et al. ALK gene rearrangement in lung adenocarcinoma. Pak Armed Forces Med J. 2023;73(Supl-1):S111-4. doi: https://doi.org/10.51253/pafmj.v73iSUPPL-1.5302 DOI: https://doi.org/10.51253/pafmj.v73iSUPPL-1.5302
Silva MVP, Santos LR, Oliveira JF, et al. Adenocarcinoma pulmonar: aspectos epidemiológicos, fisiopatológicos e terapêuticos. Rev Contemp. 2024;4(5):e4464. doi: https://doi.org/10.56083/RCV4N5-189 DOI: https://doi.org/10.56083/RCV4N5-189
Garcia F, Martinez L, Ruiz A, et al. Lung adenocarcinoma: clinical characteristics, molecular study, diagnosis and treatment. Eur Respir Soc. 2021;58(sup65):PA2184. doi: https://doi.org/10.1183/13993003.congress-2021.PA2184 DOI: https://doi.org/10.1183/13993003.congress-2021.PA2184
Conselho Nacional de Saúde (BR). Resolução n° 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União, Brasília, DF. 2013 jun 13; Seção I:59.
Lorbrena® (lorlatinibe) [bula na Internet]. [sem local]: Pfizer Laboratories Div Pfizer Inc; 2018. Bula de remédio [acesso 2025 fev 16]. Disponível em: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d
Woodhouse R, Li M, Hughes J, et al. Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PloS one. 2020;15(9):e0237802. doi: https://doi.org/10.1080/13696998.2024.2413289 DOI: https://doi.org/10.1371/journal.pone.0237802
Li M, Hou X, Chen J, et al. ALK fusion variant 3a/b, concomitant mutations, and high PD-L1 expression were associated with unfavorable clinical response to second-generation ALK TKIs in patients with advanced ALK-rearranged non-small cell lung cancer (GASTO 1061). Lung Cancer. 2022;165:54-62. doi: https://doi.org/10.1016/j.lungcan.2022.01.006 DOI: https://doi.org/10.1016/j.lungcan.2022.01.006
Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non–small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol. 2024;42(29):3400-27. doi: https://doi.org/10.1200/JCO.24.00581 DOI: https://doi.org/10.1200/JCO.24.00581
Martins AP, Casali AK, Martins AAS. Mutações no gene TP53 e suas implicações em processos de tumorigênese. Braz J Implantol Health Sci. 2023;5(5):6304-21. doi: https://doi.org/10.36557/2674-8169.2023v5n5p6304-6321 DOI: https://doi.org/10.36557/2674-8169.2023v5n5p6304-6321
Chevallier M, Borgeaud M, Addeo A, et al. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J Clin Oncol. 2021;12(4):217. doi: https://doi.org/10.5306/wjco.v12.i4.217 DOI: https://doi.org/10.5306/wjco.v12.i4.217
Makimoto G, Ohashi K, Tomida S, et al. Rapid acquisition of alectinib resistance in ALK-positive lung cancer with high tumor mutation burden. J Thorac Oncol. 2019;14(11):2009-18. doi: https://doi.org/10.1016/j.jtho.2019.07.017 DOI: https://doi.org/10.1016/j.jtho.2019.07.017
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
